Human nature meets technology in MedTech sales

Tern plc

Sales teams are asked to master products that change lives, yet the way they are trained rarely matches the complexity or urgency of the task. The numbers tell a familiar story, long onboarding times, high turnover, and widespread target misses. But beneath the statistics lies a deeper truth: much of what is taught simply does not stick.

The core issue is human nature itself. Our brains are wired to forget what we do not actively apply. Traditional sales education, the manuals, the workshops, the static presentations, leans on outdated methods that assume information can be absorbed through repetition.

The shift now underway is about changing how people learn. Artificial Intelligence, Mixed Reality, and Augmented Reality are converging to create environments where knowledge becomes experience. Instead of reading about a medical device, a sales representative can manipulate it holographically, exploring every function and feature in three dimensions. Instead of rehearsing sales pitches in abstract, they can engage with realistic AI-driven simulations that replicate the tension and unpredictability of real clinical conversations.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search